Pfizer

And so, another working week will soon draw to a close. You were waiting for this moment, yes? This is, of course, our treasured signal to daydream about weekend plans. As usual, our agenda is rather modest. We plan to putter around the castle and catch up on some reading. And what about you? This is, of course, a nice time of year to watch the leaves fall, preferably in a location that does not require you to do any raking. Or better yet, you could search for the Great Pumpkin. Intriguing, yes? Whatever you do, have a jolly old time. But please, be safe. See you soon…

Valeant Pharmaceuticals has cut ties with Philidor Rx Services, which is now shutting down. And yesterday, CVS Health, Express Scripts and Optum Rx, the three largest pharmacy benefits managers in the US, decided not to work with the mail-order pharmacy; As drug makers race to launch CAR T cells, which may be the most effective treatments ever seen for leukemia and other blood cancers, they are grappling with how to make them widely available in a reliable and cost-efficient way; Pfizer faces political risks in Washington if it proceeds with a bid for Allergan, but with little chance of legislation to curb such tax inversion deals, the Obama administration may be able to throw up only limited obstacles; and In nearly 100 news articles describing 36 cancer drugs, words like “breakthrough” and “miracle” were used, even though 50 percent of the time those drugs were not approved by the FDA.